103 related articles for article (PubMed ID: 22312906)
21. Involvement of P2 receptors in the growth and survival of neurons in the CNS.
Franke H; Illes P
Pharmacol Ther; 2006 Mar; 109(3):297-324. PubMed ID: 16102837
[TBL] [Abstract][Full Text] [Related]
22. Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states.
Donnelly-Roberts DL; Jarvis MF
Br J Pharmacol; 2007 Jul; 151(5):571-9. PubMed ID: 17471177
[TBL] [Abstract][Full Text] [Related]
23. The role of P2Y
Zhou M; Wang W; Li Y; Zhang Q; Ji H; Li H; Hu Q
Drug Discov Today; 2020 Mar; 25(3):568-573. PubMed ID: 31926135
[TBL] [Abstract][Full Text] [Related]
24. P2 receptors in health and disease.
Weisman GA; Yu N; Liao Z; Gonzaléz F; Erb L; Seye CI
Biotechnol Genet Eng Rev; 2006; 22():171-95. PubMed ID: 18476331
[TBL] [Abstract][Full Text] [Related]
25. 2', 3'-O-(2,4,6,trinitrophenyl)-ATP and A-317491 are competitive antagonists at a slowly desensitizing chimeric human P2X3 receptor.
Neelands TR; Burgard EC; Uchic ME; McDonald HA; Niforatos W; Faltynek CR; Lynch KJ; Jarvis MF
Br J Pharmacol; 2003 Sep; 140(1):202-10. PubMed ID: 12967950
[TBL] [Abstract][Full Text] [Related]
26. Purinergic receptors in skeletal muscles in health and in muscular dystrophy.
Krasowska E; Róg J; Sinadinos A; Young CN; Górecki DC; Zabłocki K
Postepy Biochem; 2014; 60(4):483-9. PubMed ID: 25807827
[TBL] [Abstract][Full Text] [Related]
27. Stimulation of lipogenesis in rat adipocytes by ATP, a ligand for P2-receptors.
Schödel J; Weise I; Klinger R; Schmidt M
Biochem Biophys Res Commun; 2004 Sep; 321(4):767-73. PubMed ID: 15358093
[TBL] [Abstract][Full Text] [Related]
28. P2 receptors in bone--modulation of osteoclast formation and activity via P2X7 activation.
Gartland A; Buckley KA; Hipskind RA; Bowler WB; Gallagher JA
Crit Rev Eukaryot Gene Expr; 2003; 13(2-4):237-42. PubMed ID: 14696970
[TBL] [Abstract][Full Text] [Related]
29. Purinergic P2 receptors: Involvement and therapeutic implications in diabetes-related glomerular injury.
Szrejder M; Rogacka D; Piwkowska A
Arch Biochem Biophys; 2021 Dec; 714():109078. PubMed ID: 34742673
[TBL] [Abstract][Full Text] [Related]
30. ATP and the pathogenesis of COPD.
Mortaz E; Folkerts G; Nijkamp FP; Henricks PA
Eur J Pharmacol; 2010 Jul; 638(1-3):1-4. PubMed ID: 20423711
[TBL] [Abstract][Full Text] [Related]
31. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells.
Kim MS; Lee J; Ha J; Kim SS; Kong Y; Cho YH; Baik HH; Kang I
Arch Biochem Biophys; 2002 May; 401(2):205-14. PubMed ID: 12054471
[TBL] [Abstract][Full Text] [Related]
32. Potential therapeutic targets for ATP-gated P2X receptor ion channels.
Li Z; Liang D; Chen L
Assay Drug Dev Technol; 2008 Apr; 6(2):277-84. PubMed ID: 18471080
[TBL] [Abstract][Full Text] [Related]
33. Molecular recognition in P2 nucleotide receptors.
Jacobson KA
Nucleic Acids Res Suppl; 2003; (3):3-4. PubMed ID: 14510351
[No Abstract] [Full Text] [Related]
34. P2 receptors, platelet function and pharmacological implications.
Gachet C
Thromb Haemost; 2008 Mar; 99(3):466-72. PubMed ID: 18327393
[TBL] [Abstract][Full Text] [Related]
35. Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes.
Thevananther S; Sun H; Li D; Arjunan V; Awad SS; Wyllie S; Zimmerman TL; Goss JA; Karpen SJ
Hepatology; 2004 Feb; 39(2):393-402. PubMed ID: 14767992
[TBL] [Abstract][Full Text] [Related]
36. Cellular distribution and functions of P2 receptor subtypes in different systems.
Burnstock G; Knight GE
Int Rev Cytol; 2004; 240():31-304. PubMed ID: 15548415
[TBL] [Abstract][Full Text] [Related]
37. Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
Shabbir M; Ryten M; Thompson C; Mikhailidis D; Burnstock G
BJU Int; 2008 Feb; 101(3):352-9. PubMed ID: 18005209
[TBL] [Abstract][Full Text] [Related]
38. New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2.
Baraldi PG; Romagnoli R; Tabrizi MA; Bovero A; Preti D; Fruttarolo F; Moorman AR; Borea PA
Farmaco; 2005 Mar; 60(3):185-202. PubMed ID: 15784237
[TBL] [Abstract][Full Text] [Related]
39. Ecto-nucleotide pyrophosphatase modulates the purinoceptor-mediated signal transduction and is inhibited by purinoceptor antagonists.
Grobben B; Claes P; Roymans D; Esmans EL; Van Onckelen H; Slegers H
Br J Pharmacol; 2000 May; 130(1):139-45. PubMed ID: 10781009
[TBL] [Abstract][Full Text] [Related]
40. A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release.
Rayment SJ; Ralevic V; Barrett DA; Cordell R; Alexander SP
FASEB J; 2007 Feb; 21(2):577-85. PubMed ID: 17167068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
